Аствацатрян А. В.

Острая ишемия миокарда и сопутствующие патологии: учебное пособие
Discipline: Медицина
 
 
ISBN: 978-5-4475-9821-1
УДК: 616.12-005.4(075)
ББК: 54.101я73
DOI: 10.23681/500385
 
Москва, Берлин: Директ-Медиа, 2019
Number of pages: 419
 

No view is available.

Bibliographic description

Annotation
В пособии отражены современные представления об острой ишемии миокарда и наиболее часто сопутствующих ей патологиях. Рассмотрены вопросы профилактики, диагностики, прогнозирования и лечения целого ряда патологических состояний, связанных с ишемией сердечно-сосудистой системы. Особое внимание уделено факторам риска, алгоритмам этапной диагностики, оценки риска, а также тактики и стратегии ведения таких больных.
Для кардиологов, врачей-терапевтов, врачей скорой медицинской помощи и студентов старших медицинских курсов.

Contents

Список литературы

1. 4S investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
2. A comparsion of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997;337:1118–23.
3. Abraham A. Ariyo et al. N Engl J Med 2003; 349:2089–90, 2108–15.
4. Acar J, lung В, Boissel JP, et al. AREVA: Multicenter randomized comparison of low-dose versus standard dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation. 1996, 94,2107–2112.
5. ACC/AHA 2002 Guideline Update for Exercise Testing. По материалам American College of Cardiology Foundation – www.acc.org и American Heart Association www.americanheart.org.
6. ACC/AHA 2002 Guideline Update for the management of patients with chronic stable angina – summary article. Circulation 2003: 107: 149–158.
7. ACCF/AHA Guideline for the Management of Heart Failure 2013: [Электронный ресурс] – Режим доступа: https:.circ.ahajournals.org/content/128/16/e240.extract [Дата обращения: 10.04.2014].
8. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomised trials. Circulation 1998;97:2202–12.
9. Adamian KG, Chilingarian AL, Astvatsatryan AL et al. Exercise induced QRS widening correlates with score index contractility and left ventricular mass but not with number and severity of diseased vessels. The Journal of Heart Disease. 1st International Congress on heart disease-new trends in research, diagnosis and treatment Washington, DC, USA, May 16–19, 1999, Volume, N1; 143.
10. Adamian KG et al. Prediction of sudden death in patients with postinfarction left ventricular remodeling. Journal of American College of Cardiology 1998, Volume 31/N5 (Supplement C); 7C-8C.
11. Adamian KG, Astvatsatrian AV, Chilingarian AL. QRS widening during treadmill test is an early predictor of post infarction left ventricular remodeling. Abstracts of the ETP entitled «Management of coronary disease in patients with heart failure» October 7–9, 1999.
12. Adamian KG, Astvatsatryan AV, Chilingarian AL et al. Exercise induced QRS prolongation is a predictor of postinfarction remodeling. The Journal of Heart Disease. 1st International Congress on heart disease-new trends in research, diagnosis and treatment Washington, DC, USA, May 16–19, 1999, Volume, N1; 61.
13. AIRE Study Investigators. Lancet 1993;342:821–8.
14. Akira Taguchi et al. Hypertension 2004; 43:1297–300.
15. Albert W Tsai et al. Arch Intern Med 2002; 162:1182–9.
16. Albert Wiegman et al. Lancet 2004; 363:369–70.
17. Albert Wiegman. Доклад на научной сессии Американской Кардиологической Ассоциации. 2003. По материалам Cardiosite.ru.
18. Alcohol 'can fight female heart disease' Febru.ary, 2002 http:.news.bbc.co.uk/hi/english/health/newsid_1832000/1832328.stm
19. Alderman MH et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34:44–150.
20. Alderman MH et al. Serum uric acid and cardiovascular risk factor for heart disease. Current Hypertension Reports 2001, 3:184–189.
21. Alexander CM et al. NCEP ATP III guidelines. Cholesterol management in the patient with diabetes. Pract Diabetol 2002; 21: 1–8.
22. Allan D. Sniderman et al. Circulation 2003; online issue for November 11th. По материалам Cardiosite.ru.
23. Ambrosioni E et al. SMILE Study Investigators. N Engl J Med 1995; 332:80–5.
24. Amento EP et al. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arteriosclerosis 1991; 11: 1223–1230.
25. American College of Cardiology Cardiovascular Technology Assessment Committee. Heart Rate Variability for Risk Stratification of Life-Threatening Arrhythmias. J Am Coll Cardiol 1993; 22: 948–50.
26. American Heart Association. Heart and stroke facts: 1997 statistical update. Dallas, Texas: National Center, 1997; AHA publication no. 33–0524.
27. Andersen K, Dellborg M. TRIM Study Group. Am J Cardiol 1998; 81: 939–44.
28. Anderson JL et al. CAST Investigators. J Am Coll Cardiol 1997; 30(1): 226–32.
29. Anderson JL. Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management. J Cardiovasc Electrophysiol 1995; 6(10 Pt 2):880–6.
30. Anderson L et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. J Am Coll Cardiol. – August 14. – 2007. – Vol. 50 (7). – P. e1e157.
31. Andrea Dunaif et al. По материалам Am J Med 2001; 111:607–13, 665–6.
32. Anker SD et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N. Engl. J. Med. 2009. 361. P. 2436–2448.
33. Anna Norhammar et al. Eur Heart J 2003;24:838–44.
34. Anna Schut et al. J Hypertens 2004; 22:313–9.
35. Anne Kousa et al. J Epidemiol Community Health 2004; 58:136–9.
36. Annelies WE. Weverling-Rijnsburger et al. Arch Intern Med 2003; 163:1549–54.
37. Anne-Sofie Furberg et al. J Natl Cancer Inst 2004;96:1152–60.
38. Annewieke W. Van den Beld et al. Am J Epidemiol 2003; 157:25–31.
39. Annie Britton et al. BMJ 2004; early online publication. По материалам Cardiosite.ru.
40. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106.
41. Antithrombotic Trialist Collaboration. BMJ 2002; 324: 71–86.
42. Antman EM et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002; 23: 308–14.
43. Antman EM et al. Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105:1642–9.
44. Antman EM et al. Results of the TIMI 11B trial. Circulation 1999; 100: 1593–601.
45. Antman EM et al. The TIMI 14 Investigators. Circulation 1999;99:2720–32.
46. Antman EM, Cohen M, Radley D et al. TIMI 11B-ESSENCE metaanalysis. Circulation 1999; 100: 1602–8.
47. Antman EM. Hirudin in acute myocardial infarction. Circulation 1996;94:911–21.
48. Anton J M. de Craen et al. Ann Neurol 2002; 51:716–21.
49. Antoni Paul et al. Circulation 2004: rapid track publication. По материалам Cardiosite.ru.
50. Aram V. Chobanian et al. The JNC 7 Report; JAMA. 2003; 289: (DOI 10,1001/jama.289.19.2560).
51. Arbustini E et al. Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty. Am J Cardiol 1995; 75: 675–82.
52. Arbustini E et al. Histopathologic features in atherectomy samples obtained from patient with unstable angina, stable angina and restenosis. Directional Atherectomy Lombardi Group. G Ital Cardiol 1996; 26: 623–33.
53. Arbustini EDBB et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999; 82: 269–72.
54. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 1994;343: 499–503.
55. Assad Movahed. Treatment of Right Ventricular Infarction. Am Fam Physician. 1999 Oct 15;60(6):1640–1649.
56. ASSENT-3 investigators. Lancet 2001; 358:605–13.
57. Astor BC et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the ARIC Study. Am Heart J. 2006. Feb; 151 (2). P. 492–500.
58. Balady GJ, et al. Circulation 2004; ASAP.
59. Barbara Alving Circulation 2004. По материалам Cardiosite.ru.
60. Barbash GI. GUSTO I and ASSENT 2 studies. Circulation 2001;103:954–60.
61. BARI investigators. JAMA 1997; 277: 715–21.
62. Bavry AA et al. Long-term benefit of statin therapy initiated during hospitalization for acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs. – 2007. – Vol. 7 (2). – P. 135–141.
63. Becker R et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial). Am J Cardiol 1996; 78: 142–7.
64. Beer 'may be good for you'. April, 2000 http:.news.bbc.co.uk/hi/english/health/newsid_727000/727912.stm
65. Belgin Unal et al. Circulation 2004; rapid access publication. По материалам Cardiosite.ru. 12.2014.
66. Bender B et al. Physician Advice and Individual Behaviors About Cardiovascular Disease Risk reduction – seven states and Puerto Rico, 1997. MMWR February 5, 1999; 48; 4; 74–77.
67. Benefits of folic acid reinforced November, 1999 http:. news.bbc.co.uk/hi/english/health/newsid_524000/524687.stm
68. Berkman LF et al. for the ENRICHD Investigators. JAMA 2003; 289: 3106–3116.
69. Berkowitz SD et al. The GUSTO I Investigators. Circulation 1997;95:2508–16.
70. Bertram Pitt et al. N Engl J Med 2003;348:1309–21, 1380–3.
71. Bertrand ME et al. CLASSICS. Circulation 2000; 102: 624–9.
72. Bigger JT Jr. The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine. J Am Coll Cardiol 1990; 15(1): 243–5.
73. Biorck G et al. Cholesterol values in patients with myocardial infarction and in a normal control group. Acta Med Scand. – 1957. – Vol. 156. – P. 493–497.
74. Blood clue to Alzheimer's risk Febru.ary, 2002 http:.news.bbc.co.uk/hi/english/health/newsid_1821000/1821147.stm
75. Boden WE, van Gilst WH, Scheldewaert RG et al. INTERCEPT. Lancet 2000; 355: 1751–6.
76. Bonthu S et al. Atherosclerosis, Vascular Remodeling, and Impairment of Endothelium-Dependent Relaxation in Genetically Altered Hyperlipidemic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. – 1997. – Vol. 17. – P. 2333–2340
77. BOOST Lancet 2004;364:141–8.
78. Bourrassa MG. «Coronairographie» en Coeur et Circulation edite par J.P. Bordarias en La pathologie Medical de Pasteur Vallery R., Hamburger J et Chermitte F. Paris 1991;336–40.
79. Braunwald E et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2000; 36: 970–1062.
80. Braunwald E et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90: 613–22.
81. Braunwald E, et al. Heart disease. A textbook of cardiovascular medicine, 3 ed. Philadelphia: Saunders Co., 1988. – 1900 p.
82. Brener SJ et al. The INTRO-AMI study. Circulation 2000; 102:11–559.
83. Brener SJ et al. The RAPPORT investigators. Am J Cardiol 1999; 84: 728–30.
84. Brener SJ et al. The RAPPORT Investigators. Circulation 1998; 98: 734–41.
85. Brieger David, et al. GRACE. Chest 2004;126:461–9.
86. Broustet JP, Douard H. Epreuve d'effort (Atlas de pratique cardiologique). CIBA-GEIGY – Paris, France. 1990.
87. Brouwer MA et al. The APRICOT – 2 Trial. Circulation 2002;106:659–65.
88. Bruce RA et al. ST segment elevation with exercise: a marker for poor ventricular function and poor prognosis. Circulation 1988;77:897–905.
89. Bueno H et al. In-hospital outcome of elderly patients with acute inferior myocardial infarction and right ventricular involvement. Circulation. 1997;96:436–41.
90. Bugiardini Raffaele, C. Noel Bairey Merz. Angina With «Normal» Coronary Arteries. JAMA. 2005;293:477–484.
91. Burke APFA, Tang AL. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276–82.
92. CABRI Investigators. Circulation 1996; 93: 847.
93. Califf RM, Topol EJ, Stack RS et al. TAMI Study Group. Circulation 1991;83:1543–56.
94. Campeau L. Letter: Grading of angina pectoris. Circulation. 1976 Sep; 54(3):522–523.
95. Cannon CP et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med. – 2004. – Vol. 350. – P. 1495–1504.
96. Cannon CP et al. The TIMI 5 trial. J Am Coll Cardiol 1994;23:993–1003.
97. CAPRIE Steering Committee. Lancet 1996; 348: 1329–39.
98. Carlos S. Kase et al. 2004. По материалам Reuters Health. http:.www.reutershealth.com.12,2014.
99. Carolina Bigert et al. Epidemiol 2003; 14:333–9.
100. Caroline Fox et al. JAMA 2004;291:844–50.
101. CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1990, 11(3): 194–9.
102. Catherine C. Cowie et al. JAMA 2004;291:335–42.
103. CCAIT. Circulation 1994;89:959–68 and Circulation 1995;92:240410.
104. CDC. Trends in ischemic heart disease mortality ~ United States, 1980–1988. MMWR 1992; 41:548–9, 555–6.
105. Chadwick Miller, et al. Internet Tracking Registry for Acute Coronary Syndromes (itrACS). Ann Emerg Med 2004; article in press. По материалам Cardiosite.ru.
106. Chaitman BR. Exercise stress testing. In: Braunwald E, ed. Heart Disease: a textbook of cardiovascular medicine, 5th edn. Philadelphia, PA: WB Saunders Co., 1997; 153–76.
107. Cheitlin MD et al. ACC/AHA guidelines for the clinical application of echocardiography. Circulation 1997;95:1686–744.
108. CHESS. Comparative HDL Efficacy and Safety Study. Am. Heart Journal № 5, November, 2003.
109. Cheuk-Kit Wong, et al. HERO Lancet 2006;367:2061–7.
110. Chinese Cardiac Study Collaborative Group. Lancet 1995;345:686–7.
111. Chris Dickens et al. Heart 2004; 90:518–22.
112. Christine E. Seidman et al. Science 2003; 299:1410–3.
113. Christine M. Albert et al. Circulation 2003; 107: rapid access issue.
114. Christine M. Thorburn, Michael M. Ward Arthritis Rheum 2003; 48:2519–23.
115. Christopher Arant et al. J Am Coll Cardiol 2004; 43:2009–14.
116. Christopher J. O’Donnell et al. Circulation 2003; rapid access issue for July 21st. По материалам Cardiosite.ru...
117. Clelend JGF et al. The CHRISTMAS Study. Eur Heart J 1999; 1; 191–6.
118. Cohell JL et al. Dobutamine digital echocardiography for detecting coronary artery disease. Am J Cardiol 1991; 67; 1311–8.
119. Cohen A et al. Hemodynamic criteria for diagnosis of right ventricular ischemia associated with inferior wall left ventricular acute myocardial infarction. Am J Cardiol. 1995;76:220–5.
120. Cohen M et al. ATACS trial. Circulation 1994;89:81–88.
121. Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the CARDS. Lancet. 2004; 364: 685–696.
122. Craig Narins et al. Arch Intern Med 2004; 164:440–6.
123. Cristina Vassalle et al. Heart 2004; 90:565–66.
124. Cristoph Nienaber et al. Circulation 2004; rapid access release. По материалам Cardiosite.ru.
125. Culleton BF et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:713.
126. Culleton BF et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999, 131:7–13.
127. Dalen JE, Hirsh J. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001;119:1S-370S.
128. Damien Bonnet et al. Lancet 2001; 358:1400–4.
129. Daniel Chasman et al. JAMA 2004; 291:2821–7.
130. Dario Giugliano et al. J Clin Endocrinol Metab 2003;88:1055–8.
131. Dariush Mozaffarian et al. J Am Coll Cardiol 2003; 41:1933–9.
132. David B. Allison et al., 2003; 289:187–93.
133. David Herrington et al. Circulation 2004;110:432–7.
134. David M. Nathan et al. N Engl J Med 2003; 348:2294–303.
135. David Tanne et al. Circulation 2001; 104:2898–2904.
136. De Luca G et al. Statin therapy and mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. Netherlands Heart Journal. – 2004. – Vol.12, № 6. – P. 271–278.
137. Debbie A. Lawlor et al. Circulation 2003; 107: rapid access issue for March 11th. По материалам Cardiosite.ru.
138. Deborah Wexler et al. American Diabetes Association 64th Annual Scientific Sessions; Orlando, Florida: June 4–8 2004.
139. Delia Johnson B. et al. Circulation 2004; rapid access publication. По материалам Cardiosite.ru.
140. Denes P, Gillis AM, Pawitan Y, et al. The CAST Investigators. Am J Cardiol 1991,68(9): 887–96.
141. Desmothenes Pahagiotakos et al. Am J Med 2004; 116:145–50.
142. Despres JP et al. The insulin-resistance syndrome: contribution of visceral obesity and therapeutic implications, Int J. Obes, 1995, 19 (Suppl.), 876–886.
143. Dessein PH et al. Dislipidemia and insulin resistance in gout: sufficiently common to be considered in the evaluation and management of every patient. AFLAR Conference. Cape Town, South Africa, September 1999. Cape Town: Ukenza 1999.
144. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447–55.
145. Dohi Y, Luscher TF. Endothelin in hypertensive resistance arteries.
146. Intraluminal and extraluminal dysfunction. Hypertension. – 1991. – Vol. 18, № 4. – P. 543–549.
147. Don Poldermans et al. Arch Intern Med 2003;163:2230–5.
148. Donald Lloyd-Jones et al. JAMA 2004; 291:2204–11.
149. Dorn J et al. NEHDP. Circulation 1999;100:1764–9.
150. Dreifus LS et al. Guidelines for the implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol. 1991;18:1–13.
151. Dyke CM et al. Results from PURSUIT. Ann Thorac Surg 2000; 70: 866–71; discussion 871–2.
152. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch. Intern. Med. – 1993. – Vol. 153. – P. 937–942.
153. Eagle KA et al. GRACE. Lancet 2002; 359: 373–7.
154. Earl S. Ford et al. JAMA 2002; 287:356–9.
155. Ellis SG et al. RESCUE I, RESCUE II. Am Heart J 2000; 139: 10461053.
156. EPIC Investigators. N Engl J Med 1994; 330: 956–61.
157. EPILOG investigators. N Engl J Med 1997; 336: 1689–96.
158. EPISTENT Investigators. Lancet 1998; 352: 87–92.
159. Erica P. Gunderson et al. По материалам на 43-ей ежегодной конференции Американской Кардиологической Ассоциации по эпидемиологии и профилактике сердечно-сосудистых заболеваний с использованием материалов Cardiosite.ru... 7,2002
160. ESPRIT Investigators. Lancet 2000; 356: 2037–44.
161. Eugenio Picano J Am Coll Cardiol 2003. По материалам Cardiosite.ru.. 2003.
162. European Society of Hypertension XIV annual meeting; Paris, France: 13–17 June 2004. По материалам.
163. Expert consensus document on beta–adrenergic receptor blockers. The Task Force on beta–blockers of the European Society of Cardiology.
164. Eur. Heart J. 2004; 25:1341–1362.
165. F McAlister et al. BMJ 2004; online first issue. По материалам Cardiosite.ru.
166. Fabio Angeli et al. Hypertension 2003; 41:488–92.
167. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality.
168. The NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000;283:24042410.
169. Fang J, Alderman MN: Serum uric acid and cardiovascular mortality – The NHANES 1 Epidemiologic Follow – up Study, 1971–1992. JAMA 2000, 283:2404–2410.
170. Farag H. et al. Fertil Steril 2003; 79:256–60.
171. Farb ABA, Tang AL. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354–63.
172. Farouk Mookadam and Heather Arthur. Arch Intern Med 2004;164:1514–8.
173. Farre J, Moro C. Primum non nocere: the end of CAST II. Cardiac Arrhythmia Suppression Trial (editorial). Rev Esp Cardiol 1991;44(10):632–3.
174. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. Press Release. Accessed February 28, 2012.
175. Ferdinando Sasso et al. JAMA 2004; 291:1875–63.
176. Fihn SD et al. 2012 ACCF/AHA/ACP/FCP/AATS/PCNA/SCAI/ SNS
177. Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. J. Am. Coll. Cardiol. 2012. Vol. 60. № 24. P. e44-e164
178. Fiore L, Ezekowitz MD, Brophy MT et al. CHAMP. Circulation 2002;105:557–63.
179. Flaker GC, Warnica JW, Sacks FM et al. CARE Investigators. J Am Coll Med 1999;34:106–12.
180. Fletcher GF, Balady G, Froelicher VF, et al. Exercise standarts: a statement for healthcare professionals from the American Heart Association. Circulation 1995; 91: 580–615.
181. Focused update of the ACC/AHA (2007) Guidelines for the management of patients with ST-elevation myocardial infarction (2004). J Am Coll Cardiol. – 2008. – Vol. 51. – P. 210–247.
182. Folic acid 'heart boost for elderly' March, 2002 http:.news.bbc.co.uk/hi/english/health/newsid_1856000/1856060.stm
183. Folic acid tested on heart patients August, 2001 http:.news.bbc.co.uk/hi/english/health/newsid_1504000/1504047.stm
184. Fonarow GC et al. National Registry of myocardial infarction 4 investigators. Effect of statin within the furst 24 hours of admission for
185. acute myocardial infarction on early morbidity and mortality. Am J Cardiol. – 2005. – Vol. 96. – P. 611–616.
186. Foo K et al. British Cardiac Society Annual Scientific Conference; Manchester, UK: 24–27 May 2004. По материалам Cardiosite.ru./.11,2014.
187. Fox K et al. GRACE. Eur Heart J 2002; 23: 1177–89.
188. Fox KA. OASIS-2. Am J Cardiol 1999; 84: 26M – 31M.
189. Framework Convention on Tobacco Control, FCTC. www.fctc.org
190. France LV, Pahor M, Di Bari M, et al. SHEP. J Hypertens 2000, 18:1149–1154.
191. Francesco Cippolone et al. JAMA 2004; 291:2221–8.
192. Francesco Iemolo et al. Stroke 2004; 35: online first publication. По материалам Cardiosite.ru.
193. Frankel WL et al. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996; 106: 118–23.
194. Franse LV et al. Serum uric acid diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Progran (SHEP). J Hypertens 2000;18:1149–1154.
195. FRAXIS study group. Eur Heart J 1999; 20: 1553–62.
196. Frederickson DS, Lee RS. A system for phenotyping hyperlipidemia.
197. Circulation 1965;31:321–7.
198. Freedman DS et al. NHANES 1 epidemiologic followup study. Am J Epidemiol 1995; 141:637–44.
199. FRISC II investigators. Lancet 1999; 354: 708–15.
200. Frostfeldt GAG et al. BIOMACSII. J Am Coll Cardiol 1999; 33: 627–33.
201. FTT Trialists. Lancet 1994; 343: 311–22.
202. Gad Cotter et al. Am Heart J 2003; 145:622–7.
203. Gaetano Vaudo et al. Ann Rheum Dis 2004; 63:31–5.
204. Galle J, Heermeier K. Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress. Nephrol. Dial. Transplant. – 1999. – Vol. 14. – P. 2585–2589.
205. Gary D. Slade et al. Arch Intern Med 2003; 163:1172–9.
206. Geleijnse ML et al. Safety and tolerability of dobutamine-atropine stress echocardiography in patients with suspected or coronary artery disease: experience in 650 consecutive examinations. Am J Cardiol 1994; 73: 456–9.
207. Geleijnse ML et al. Should the diagnosis of coronary artery disease be based on the evalution of myocardial function or perfusion? Eur Heart J 1997;18 (suppl D):68–7.
208. Genjiro Kimura et al. Hypertension 2003;42.
209. George T. Kondos et al. Circulation 2003; 107.
210. Gerald M. Reaven et al. J Am Coll Cardiol 2002; 40.
211. Gerald S. Werner et al. Eur Heart J 2003;224:1134–42.
212. Giles Montalescot et al. JAMA 2004;292:362–6. 207. GISSI-3. Lancet 1994;343:1115–22.
213. Giuseppe Schillaci et al. Am J Hypertens 2003; 16:634–9.
214. Glassman AH et al. SADHEART Group. JAMA 2002 Oct 9;288(14):1720.
215. Goran Walldius et al. Lancet 2001; 358:2012–3, 2026–33.
216. Gore JM et al. GUSTO-I trial. Circulation 1995;92:2811–8.
217. Gottlieb SO. Diagnostic procedures for myocardial ischaemia. Eur Heart J 1996;17 (suppl G):53–8.
218. Goya Wannamethee S. Serum Uric Acid Is Not an Independent Risk Factor for Coronary Heart Disease. Current Hypertension Reports 2001, 3:190–196.
219. Goyal A et al. FRISC-II trial … VANQWISH trial. J Am Coll Cardiol 2002, 39(10): 1601–7.
220. GRACE I. Am Heart J 2001; 141: 190–9.
221. Granger CB et al. GUSTO-I trial. Circulation 1996;93:870–8. 217. GREAT Group. BMJ 1992;305:548–53.
222. Gregory Ewald. Journal of the American Medical Association, 21 мая
223. 2003 г. По материалам Cardiosite.ru.
224. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. European Heart Journal. – 2007. – Vol. 28. – P. 1598–1660.
225. Guido Schynder et al. Am J Cardiol 2003; 91:1265–8.
226. Guillaume Bobrie et al. JAMA 2004; 291:1342–9.
227. Gunnar Engstrom et al. Arterioscler Thromb Vasc Biol 2003; 23:2247–51.
228. Gusto IIB investigators. GUSTO IIb investigators. N Engl Jmed 1996; 335: 775–82.
229. GUSTO IIb. N Engl J Med 1997;336:1621–8.
230. GUSTO-IV ACS Investigators. Lancet 2001; 357: 1915–24.
231. Haakenson C et al. FASHP for the CAPS Investigators. Control Clin Trials 1996,17(4):294–303.
232. Haffner SM, Lehto S, Rannemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes with and without prior
233. myocardial infarction/ N Engl J Med 1998; 339(4): 229–234.
234. Hamm CW et al. CAPTURE. N Engl J Med 1999; 340: 1623–9.
235. Hamm CW et al. GABI. N Engl J Med 1994; 331: 1037–43.
236. Hang G et al. Direct enzyme immunometric measurement of plasma big endothelin-1 concentrations and correlations with indicators of left ventricular function. Clin. Chem. – 1998. – Vol. 44. – P. 239–243.
237. Hanna Kalvegren et al. По материалам Cardiosite.ru. 2003.
238. Hanna-Maaria Lakka et al. JAMA 2002; 288:2709–16.
239. Hans-Peter Kopp et al. Arterioscler Thromb Vasc Biol 2003;23:1042–7.
240. Harlan M. Krumholz et al. J Am Coll Cardiol 2003;41:1510–22.
241. Harrison D.G. Endothelial function and oxidant stress. Clin. Cardiol. – 1997. – Vol. 20. – P. 11–17.
242. Hasin T et al. Prevalence and Prognostic Significance of Transient, Persistent, and New-Onset Anemia After Acute Myocardial Infarction. Am J Cardiol. 2009. Aug 15; 104 (4). P. 486–491.
243. Heeschen C et al. PRISM Study Investigators. Lancet 1999; 354: 1757 – 62.
244. Hemming Tiemeier et al. Arch Gen Psychiatry 2004;61:369–76.
245. Hill Golden S. Prevention of coronary heart disease in the metabolic syndrome and diabetes mellitus. Adv Stud Med 2002; 2: 364–371.
246. Hiroaki Kawano et al. J Clin Epidemiol Metab 2003; 88:3190–5.
247. Hochman JS et al. SHOCK Investigators. N Engl J Med 1999;341:625 – 34.
248. Hoieggen A et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041–1049.
249. Horan LG, Flowers NC. Right ventricular infarction: how cardiac management differs from usual. Am Fam Physician. 1999;60:1727–34.
250. Howard D. Sesso et al. Hypertension 2003:42:885–90.
251. Hsia J et al. HART Investigators. N Engl J Med 1990;323:1433–7.
252. Hudson MP et al. GUSTO III trials. Circulation 2001; 104: 1229–35.
253. Hugh E. Montgomery et al. Hypertension 2003; 42:500–6.
254. Ian R. Reid et al. Am J Med 2002;112:343–7.
255. Ichiro Kawachi et al. The Normative Aging Study.Symptoms of Anxiety and Risk of Coronary Heart Disease. Circulation Vol 90, No 5 November 1994.
256. Ichiro Wakabayashi, Rie Kobaba-Wakabayashi. Gerontology 2002; 48:151–6.
257. Ihab Hajjar, Theodore A. Kotchen JAMA 2003; 290:199–206.
258. Ilan Goldenberg et al. Arch Intern Med 2003;163(19):2301–5.
259. Ileana L. Pina et al. Circulation 2003;107:1210–25.
260. IMPACT-II Investigators. Lancet 1997; 349: 1422–8.
261. International Diabetes Federation. Diabetes prevalence. International Diabetes Federation Website, 2003. http:.www.idf.org/home/index.cfm?node=264, accessed January 28, 2004.
262. IONA Study Group. E Lancet 2002; 359: 1269–75.
263. Ischa Stranders et al. Arch Intern Med 2004; 164:982–8.
264. ISIS-2 Collaborative Group. Lancet 1988;II:349–60.
265. ISIS-3 Collaborative Group. Lancet 1992;339:753–70.
266. ISIS-4 Collaborative Group. Lancet 1995;345:669–85.
267. Jala K. Ghali et al. J Am Coll Cardiol 2003; 42: 2128–34, 2135–7.
268. James A. Blumenthal et al. Lancet 2003;362:604–9.
269. James D. Neaton et al. JAMA 2002; 287:2677–83.
270. James V. Tedesco et al. Mayo Clin Proc 2003;78:561–6.
271. Janet McGill et al. American Diabetes Association 64th Annual Scientific Sessions; Orlando, Florida: June 4–8 2004. По материалам Cardiosite.ru.
272. Jay N. Cohn et al. Am J Hypertens 2003; 16:265–9.
273. Jean C. McSweeney et al. Circulation 2003; rapid access issue for November 4th. По материалам Cardiosite.ru.
274. Jiang He et al. Ann Intern Med 2003; 138:891–7.
275. Joaquin Barnoya и Stanton Glanz Am J Med 2004; По материалам Cardiosite.ru.
276. Johanna M. Geleijnse et al. Hypertension 2003; 42:878–84.
277. John Danesh et al. N Engl J Med 2004; 350:1387–97.
278. Johnson RJ et al. Subtle acquired renal injury as a mechanism of saltsensitive hypertension. N Engl J Med 2002;346:913–923,39.
279. Jose Ramon Banegas et al. Eur J Clin Nutr 2003; 57:201–8.
280. Jose Zamorano et al. Int J Cardiol 2003; 89:273–9.
281. Joseph I. Miller et al. J Am Coll Cardiol 2003; 41:521–31.
282. Judith Hsia et al. Am J Cardiol 2004; 93:673–8.
283. Julian DG et al. AFTER Study. Brit Med J 1996;313:1429–1431.
284. Julie Anne et al. Hoff J Am Coll Cardiol 2003; 41:1008–12.
285. Kaartinen A et al. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669–78.
286. Kaartinen M et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol 1998; 32: 606–12.
287. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000;13:1:Pt.2:3S-10S.
288. Karen A. Matthews, Brooks B. Gump. Arch Intern Med 2002; 162:309–15.
289. Karen Grewen et al. Psychosom Med 2004; online issue. По материалам Cardiosite.ru.
290. Karen P. Alexander et al. CRUSADE Investigators. Circulation 2006;114:1380.
291. Karlsson JE et al. TRIC Study Group. Am Heart J 1992; 124: 1419–26.
292. Karsten Pohle et al. Heart 2003; 89:625–8.
293. Katz SD et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. – 2005. – Vol. 111. – P. 310–314.
294. Kayikcioglu M et al. The effect of statin therapy on ventricular late potentials in a myocardial infarction. Int J Cardiol. – 2003. – Vol. 90. – P. 63–72.
295. Kazuko Ishikawa-Takata et al. Am J Hypertens 2003;16:629–33.
296. Kazuko Masuo et al. Hypertension 2003; 42:474–80.
297. Kazuo Eguchi et al. Am J Cardiol 2003;92:621–4.
298. Keaney JJ, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium – derived relaxing factor action. Prog. Cardiovasc. Dis. – 1995. – Vol. 38. – P. 129–154.
299. Kelly J. Hunt et al. Arterioscler Thromb Vasc Biol 2003; 23:1845–50.
300. Keltikangas-Jarvinen. 2004 По материалам http:.www.mdconsult.com/
301. Kerkalainen P et al. Long-term association of cardiovascular risk factors with impaired insulin secretion and insulin resistance. Metabolism 2000; 49:1247–1254.
302. Khare A, Shetty S, Ghosh K. Evaluation of markers of endothelial damage in case of young myocardial infarction. Atherosclerosis. – 2005. – Vol. 18. – P. 375–380.
303. Khurram Nasir et al. Fifth annual conference on Arteriosclerosis, Thrombosis, and Vascular Biology: San Francisco, California, USA: 6–8 May 2004. По материалам Cardiosite.ru..
304. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20:457–64.
305. Kim Sutton-Tyrell et al. J Am Coll Cardiol 2004;44:579–85.
306. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994; 330:1211–7.
307. King H, Aubert RE, Herman WH. Global burden of diabetes, 19952025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414–1431.
308. King SB 3rd et al. EAST. N Engl J Med 1994; 331: 1044–50.
309. Kinn JW et al. Rapid hemodynamic improvement after reperfusion during right ventricular infarction. J Am Coll Cardiol. 1995;26:1230–4.
310. Kjeldsen SE et al. for the LIFE Study Group. JAMA 2002;288:1491–1498.
311. Kleiman NS, Califf RM. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. J Am Coll Cardiol 2000;36:310–25.
312. Klootwijk P et al. CAPTURE. Circulation 1998; 98: 1358–64.
313. Kober L et al. TRACE Study Group. N Engl J Med 1995;333:1670–6.
314. Kontny F et al. FRAMI. J Am Coll Cardiol 1997;30:962–9.
315. Koval M. Medicine Review 2008; 5 (05): 32–36.
316. Kristian Wachtell et al. Ann Intern Med 2003; 139:901–6.
317. Kristin Newby et al. Fifth Scientific Forum on Quality of care and Outcomes Research in Cardiovascular Disease and Stroke; Washington, DC: 15–17 May 2004.
318. Krittayaphong R et al. Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Psychosom Med. 1997 May-Jun; 59(3):231–5.
319. Kubansky L et al. Anxiety and coronary heart disease: A synthesis of epidemiological psychological, and experimental evidence. Am Behav Med. 1998;20:47–58.
320. Kuller LH et al. MRFIT. Am J Epidemiol 1996; 144: 537–47.
321. La Roverte MT, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003;107:565–570.
322. Lagerqvist B et al. FRISC II Study Group Investigators. J Am Coll Cardiol 2001; 38: 41–8.
323. Langer A et al. The GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998;31:783–9.
324. Laplante M et al. Role of endothelin in the stimulation of NAD(P)H oxydase and superoxyde production in vascular smooth muscle cells
325. following a treatment with angiotensin II. J. Hypertens. – 2003. – Vol. 21, Suppl. 4. – P. 200–206.
326. Laster SB et al. Effects of reperfusion on ischemic right ventricular dysfunction. Disparate mechanisms of benefit related to duration of ischemia. Circulation. 1994; 90: 1398–409.
327. Laszlo B Tanko et al. Circulation 2003; 107.По материалам Cardiosite.ru.
328. Leclercq JF et al. Mise en evidence des mechanismes de la morte subite. Arch Mal Coeur 1986; 79: 1024–33.
329. Leo G et al. Right Ventricular Infarction: Specific Requirements of Management. Am Fam Physician. 1999 Oct 15;60(6):1727–1734.
330. Leo Niskanen et al. Arch Intern Med 2004;164:1546–51.
331. Leslie Kinder et al. Psychosomatic Medicine 2004;66:316–22.
332. Lev EI et al. Comparison of the predictive value of four different risck scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cariol. – 2008. – Vol. 102, № 1. – P. 6–11.
333. Levels James H. Stein et al. Smoking Cessation, but Not Smoking Reduction, Reduces Plasma Homocysteine January 2002: Contents Clin. Cardiol. 25, 23–26 (2002).
334. Levin ER. Endothelins. New Engl. J. Med. – 1995. – Vol. 10, № 6. – P. 356–363.
335. Lewis HD Jr et al. Results of the Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403.
336. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365–72.
337. Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995; 91: 2844–50.
338. Linda Peterson et al. J Am Coll Cardiol 2004; 43:1399–404.
339. Lindahl B et al. FRISC II substudy. J Am Coll Cardiol 2001; 38: 979–86.
340. Lindahl B et al. FRISC Study Group. N Engl J Med 2000; 343: 1139–47.
341. Link A et al. Rapid immunomodulation by rosuvastatin in patients
342. with acute coronary syndrome. Eur Heart J. – 2006. – Vol. 27 (24). – P. 2945–2955.
343. Lorenz H et al. Do statins influence the prognostic impact of nonsustained ventricular tachycardia after ST-elevation myocardial infarction? Eur Heart J. – 2005. – Vol. 26 (11) – P. 1078–1085.
344. Lori Mosca et al. Circulation 2004; 109:573–9, 672–93.
345. Luc Djousse et al. По материалам Stroke 2003; 34:53–7.
346. Luepker RV et al. REACT trial. JAMA 2000;284:60–7.
347. Luigi M. Biasucci et al. Circulation 2003; 107: rapid access issue for June 9th.
348. Luscher MS et al. TRIM Study Group. Circulation 1997; 96: 2578–85.
349. Luscher TF et al. Endotheliale dysfunction und stickstoffmonoxid (NO; Nitric Oxide). Internist. – 1997.
350. MacIsaac AI et al. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993; 22: 128–141.
351. Madsen JK et al. DANAMI. Circulation 1997;96:748–55.
352. Maggioni AP et al. GISSI-2 results. Circulation 1993;87:312–22.
353. Maggioni AP et al. GISSI-2. N Engl J Med 1992;327:1–6.
354. Mahboob Rahman et al. Arch Intern Med 2004; 164:969–76.
355. Malyszko J et al. Prevalence of chronic kidney disease and anemia in patients with coronary artery disease with normal serum creatinine undergoing percutaneous coronary interventions: relation to New York Heart Association class. Isr Med Assoc J. 2010. 12. P. 489–493.
356. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal. – 2008. – Vol. 29. – P. 2909–2945.
357. Manuel Martinez-Selles et al. Eur Heart J 2003;24:2046–53.
358. Manuel Quinones et al. Ann Intern Med 2004; 140:700–8.
359. Mario J. Veerkamp et al. Arterioscler Thromb Vasc Biol 2002; 22:274–82.
360. Mark J. Sarnak et al. Circulation 2003; 108:2154–69.
361. Mark Pletcher et al. Arch Intern Med 2004; 64:1285–92.
362. Martha Gulati et al. Circulation 2003;108: online issue for September 30th.
363. Mary A. Whooley et al. JAMA 2003;290:215–21.
364. Mary Cushman et al. Circulation 2003:108: rapid access issue for June 24th. По материалам Cardiosite.ru.
365. Mary M. McDermott et al. J Am Geriatr Soc 2003; 51: По материалам Cardiosite.ru.
366. Masaharu. Ishihara et al. Am Heart J 2003;146:674–8.
367. Masahisa Shimpo et al. Circulation 2004; 109:2186–90.
368. McNulty et al. Am J Cardiol 2003; 91:956–68.
369. McVeigh G et al. Effects of long-term cigarette smoking on endothelium-dependent responses in humans. Am. J. Cardiol. – 1996. – Vol. 78. – P. 668–672.
370. Mehta SR et al. PCI-CURE study. Lancet 2001; 358: 527–33.
371. Mehta SR, Yusuf S. The CURE trial programme. Eur Heart J 2000; 2: 2033–2041.
372. Meijer A et al. Results of the APRICOT Study. Circulation 1993;87: 1524–1530.
373. Memorandum from a WHO/JSH meeting – 1993 Gidelines for management of mild hypertension. Clin Exp Hypertens 1993; 15:1363–95.
374. Meneveau N et al. Anemia for Risk Assessment of Patients With Acute Coronary Syndromes. Am J Cardiol. 2009. Feb 15; 103 (4). P. 442–447.
375. Miami Trial research group. Metoprolol in myocardial infarction. Eur. Heart J 1985; 6: 199–226.
376. Michael B. Jorgensen et al. Am Heart J 2003; 146:1077–81.
377. Michael Ong et al. Am J Med 2004; 117:32–8.
378. Michiaki Fukui et al. JAMA 2003; 289:1245–6.
379. Miettinen H et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21(1): 69–75.
380. Mitchell LB and the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An Analysis of the Antiarrhythmic Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol. – 2003. – Vol. 42. – P. 81–87.
381. Monika Ehrhart-Bornstein et al. Proceedings of the National Academy of Sciences USA 2003; online issue for November 10th. По материалам Cardiosite.ru.
382. Montalescot G et al. STEMI and NSTEMI: Are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA Registry). Eur Heart J. – 2007. – Vol. 28 (12). – P. 1409–1417.
383. Moreno PR et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775–8.
384. MRC/BHF Lancet 2002;360:7–22.
385. MRFIT: Circulation 1995;92:2437–45;
386. Mueller HS et al. TIMI trial, phase II. Circulation 1992;85:1254–64.
387. Muñoz M et al. Preoperative Anemia in Elective Cardiac Surgery: Prevalence, Risk Factors, and Influence on Postoperative Outcome. Transfusion Alternatives in Transfusion Medicine. 2010. 11 (2). P. 47–56.
388. N TIMI IIIB investigators. Circulation 1994; 89: 1545–56.
389. Nagueh SF et al. Stress echocardiography for the assessment of myocardial ischemia and viability. Curr Probl Cardiol 1996;21:445–520.
390. Naito Y et al. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol. 2009. 296. P. 585–593.
391. Najib T. Ayas et al. Arch Intern Med 2003; 163:205–9.
392. Nathan Wong et al. Am J Cardiol 2003; 91:1421–6.
393. National Institute of Health. Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung and blood disease, Bethesda: US Department on Heart and Human Services, Public Health Service; 2004.
394. Naveed Sattar et al. Circulation 2003 с использованием Cardiosite.ru. [7,2004]
395. NCHS. Health United States, 1995. Hyattsville, MD: US Department of Health and Human Service, CDC, National Center for Health Statistics, May 1996; DHHS publication no. (PHS) 96–1232.
396. Newby LK et al. GUSTO trial. J Am Coll Cardiol 1996;27:625–32.
397. Newman C et al. Comparative Safety of Atorvasatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiology. 2006; 97: 61–67.
398. Noel C. Bairey Merz et al. Am Coll Cardiol 2003; 41:413–9.
399. Nystrom T et al. Persistent endothelial dysfunction is related to elevated C-reactive protein levels in type II diabetic patients after acute myocardial infarction. Clin. Science. – 2005. – Vol. 12. – P. 121–128.
400. Olli T. Raitakari et al. JAMA 2003; 290:2277–83.
401. Ordway AG, Garry DJ. Myoglobin: an essential hemoprotein in striated muscle. J Exp Biol. 2004. 20; 7. P. 3441–3446.
402. Ortiz E et al. Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res. 2004. 77. P. 681–689.
403. Paivi Pajukanta et al. Nature Gen 2004; advance online publication. По материалам Cardiosite.ru.
404. Paolo Prandoni et al. N Engl J Med 2003; 348:1435–42.
405. Paolo Rubba et al. Stroke 2002; rapid access issue for November 15th. http:.www.strokeaha.org.
406. PARAGON Investigators. Circulation 1998; 97: 2386–95.
407. PARAGON-B investigators. Circulation 2002; 105: 316–21.
408. Pasternak RC et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567–72.
409. Patrik Stolt et al. Ann Rheumat Dis 2003; 62:835–41.
410. Paul Poirier et al. Am J Med 2003; 114:599–601.
411. Paul W. Armstrong et al. Arch Intern Med 2003; 163:2476–84.
412. Pelat M et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprorein E mice in vivo. Circulation. – 2003. – Vol. 107. – P. 2480–2486.
413. Pesus Chou et al. J Clin Epidemiol 2002;55:19–24.
414. Peter Mason et al. Circulation 2004; rapid access publication. По материалам Cardiosite.ru.
415. Peter Whincup et al. BMJ 2004; online first issue. По материалам Cardiosite.ru.
416. Pettersson T et al. Increased CKMB (mass concentration) in patients without traditional evidence of acute myocardial infarction. Eur Heart J 1992; 13: 1387–92.
417. Pfeffer MA, Hennekens CH. HEART trial. Am J Cardiol 1995;75:1173–5.
418. Philip Poole-Wilson et al. COMET 2003. По материалам Cardiosite.ru.
419. Philip S. Tsao et al. JAMA 2002; 287:1420–6, 1451–2.
420. Pitt B et al. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. – 2008. – Vol. 51. – P. 1440–1445.
421. Pliquett RU et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. – 2003. – Vol. 107. – P. 2493–2498.
422. Pocket Guide to Prevention of Coronary Heart Disease. January 2003. (http:.www.chd-taskforce.de/pdf/pocket_guide_engl.pdf):
423. POZNAN. По материалам Конгресса Американской Коллегии Кардиологов 2004 года. http:.athero.ru./www.acc04online.org
424. Prikko J. Pussinen et al. Arterioscler Thromb Vasc Biol 2003; 23:1250–4.
425. Prinzmetal M et al. Angina pectoris. 1. A variant form of angina pectoris. JAMA 1959;27: 375–88.
426. PRISM Study Investigators. N Engl J Med 1998; 338: 1498–505.
427. PRISM-PLUS Study investigators. N Engl J Med 1998; 338: 1488 – 97.
428. Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:7:869–872.
429. PURSUIT Investigators. N Engl J Med 1998; 339: 436–43.
430. Rachel Lampert et al. J Am Coll Cardiol 2004; 43:2293–9.
431. Ralph AH et al. Eur Heart J 2003;24:2927–37.
432. Ramachandran S. Vasan et al. Hypertension 2003; 42:1100–5.
433. Ramachandran Vasan et al. Framingham Heart Study N Engl J Med 2004; 351:33–41.
434. Raphael Rosenhek et al. Eur Heart J 2004; 25:199–205.
435. Reaven GM. The kidney: An unwilling accomplice in syndrome X. Am J Kidney Dis 1997;30:928–931.
436. RESTORE Investigators. Circulation 1997; 96: 1445–53.
437. Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–9.
438. Richard J. Stevens et al. Diabetes Care 2003;27:201–7.
439. Richard M. Cawthon et al. Lancet 2003; 361:394–5.
440. Richard S Cooper et al. JAMA 2003; 289:2363–9, 2420–2.
441. Ridker PM et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767–1772.
442. RISC Group. Lancet 1990; 336: 827–30.
443. RITA investigators. Lancet 1993; 341: 573–80.
444. Robbert J. de Winter et al. Am J Med 2003; 115:85–90.
445. Robert C. Detrano et al. JAMA 2004;291:210–5.
446. Robert Dluhy, Gordon Williams. N Engl J Med 2004. По материалам Cardiosite.ru. [9,2013].
447. Roberts R et al. TIMI II-B Study. Circulation 1991;83:422–37.
448. Rodriguez A, et al. ERACI Group. J Am Coll Cardiol 1993; 22: 1060 – 7.
449. Rose Christian et al. J Clin Endocrinol Metab 2003; 88:2562–8.
450. Ross AM, Molhoek P, Lundergan C et al. HART II. Circulation 2001;104:648–52.
451. Ruilope LM et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218–225.
452. Russell V Luepker. Minnesota Heart Survey. Доклад на 43-ей ежегодной конференции Американской Кардиологической ассоциации по эпидемиологии и профилактике ССЗ. Майами 2003 г. По материалам Cardiosite.ru.
453. Ryan TJ et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996;28:1328– 428.
454. Ryan TJ et al. ACC/AHA Guidelines for the management of patients with acute MI: 1999 Update. J Amer Coll Cardiol 1999; 34:890–911.
455. Samuel Klein et al. N Engl J Med 2004; 350:2549–57.
456. San Roman JA et al. Right ventricular asynergy during dobutamineatropine echocardiography. J Am Coll Cardiol. 1997;30:430–5.
457. Savonitto S et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. – 1999. – Vol. 281. – P. 707713.
458. Schlant RC. Prevention of sudden cardiac death: lessons from CAST. J Med Assoc Ga 1990;79(4):245–7.
459. Schrecengost JE et al. Comparison of diagnostic accuracies in outpatients and hospitalized patients of D-dimer testing for the evaluation of suspected pulmonary embolism.. Clinical chemistry. – 2003. – Vol. 49. – № 9. – P. 1483–1490.
460. Scientific Research into a Cure http:.www.bbc.co.uk/health/heart/prevention_cure.shtml
461. Scientists uncover Alzheimer's clues June, 2000 http:.news.bbc.co.uk/hi/english/health/newsid_803000/803297.stm
462. Scott Grundy et al. Circulation 2004; 110:227–39.
463. Shah Ebrahim et al. BMJ 2004; 328:861.
464. Sharma S et al. Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. Am Heart J. 2009. Jun; 157 (6). P. 1057–1063.
465. Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J. Mol. Cell. Cardiol. – 1999. – Vol. 31. – P. 23–37.
466. Simon E et al. Atherosclerosis, 2001.
467. Simoons ML et al. The AMI-SK study. Eur Heart J 2002;23:1282–90.
468. Singh BN eds. Electropharmacologicl Control of Cardiac Arrhythmias; to Delay Conduction or to Prolong Refractoriness? Mt Kisco. NY. Futura Publishing 1994; 1–713.
469. Smoking Research J Am Coll Cardiol 2000; 36:878–883.
470. Sofia Carlsson et al. Diabetes Care 2003;26:2785–90.
471. Sok-Ja Janket et al. Circulation 2004; rapid access publication. По материалам Cardiosite.ru.
472. SOLVD investigators. E NEngl J Med 1992; 327: 685–91.
473. Solveig Wallberg-Jonsson et al. J Rheumatol 2001; 28:2597.
474. Sotirios Tsimikas et al. J Am Coll Cardiol 2003; 41:360–70.
475. SPEED. Circulation 2000;101:2788–94.
476. Starling MR et al. First transit and equilibrium radionuclide angiography in patients with inferior transmural myocardial infarction: criteria for the diagnosis of associated hemodynamically significant RV infarction. J Am Coll Cardiol. 1984;4:923–30.
477. Stavroula K. Osganian et al. J Am Coll Cardiol 2003; 42:246–55.
478. Stefanadis C et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter. Circulation 1999;99:1965–1971.
479. Stein RA et al. Safety and utility of exercise testing in emergency room chest pain centers: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 2000;102:1463–7.
480. Steinberg EH et al. Long-term prognostic significance of dobutamine echocardiography in patients with suspected coronary artery disease:
481. results of 5-year follow up study: sensitivity, specificity and predictive value for future cardiac events. J Am Coll Cardiol 1997;29:960–73.
482. Stenestrand U, Wallentin L. Early revascularization and 1-year survival in 14-days survivors of acute myocardial infarction: a prospective cohort study. Lancet 2002; 359:1805–11.
483. Stenestrand U, Wallentin L. Early statin treatment following acute
484. myocardial infarction and 1-year survival. JAMA. – 2001. – Vol. 285. – P. 430–436.
485. Stephanie Schuit et al. JAMA 2004; 291:2969–71.
486. Stephen Gottlieb et al. J Am Coll Cardiol 2004;43:1542–9
487. Stephen Morewitz et al. Fifth Scientific Forum on quality of care and Outcomes Research in Cardiovascular Disease and Stroke; Washington, D.C., 15–17 May 2004.
488. Stone PH et al. PIMI study. J Am Coll Cardiol. 1999 May;33(6):1476–84.
489. Stress testing for the diagnosis of coronary artery disease in the 1990s. report of a symposium. Piza, Italy, 1989. Circulation 1991; 83(Suppl 5):111–5.
490. Stroke Prevention in Atrial Fibrillation Investigators. Lance. 1996; 348:633–8.
491. Sutton SG et al. MERLIN trial. J Am Coll Cardiol 2004; 44: 287–296.
492. Swedberg K et al. CONSENSUS II. N Engl J Med 1992;327:678–84.
493. SWIFT trial. BMJ 1991; 302:555–60.
494. Sylvia Wassertheil-Smoller et al. Arch Intern Med 2004;164:289–98.
495. SYMPHONY Investigators. Lancet 2000; 355: 337–45.
496. Ted Calonge et al. Ann Intern Med 2004; early release article. По материалам Cardiosite.ru.
497. Tetsunori Ischikawa et al. Am J Cardiol 2003; 91:287–92.
498. The CHAMP rates of major hemorrhage. Poster presented at: 39th Annual Scientific Session of the American College of Cardiology; March 12–17, 2000; Anaheim, CA.
499. The Beta-Blocker Pooling Project Research Group. Eur Heart J 1988;9:8–16.
500. The BIP Study Group. Circulation 2000;102:21–7.
501. The CAPRICORN investigators. Lancet 2001;357:1385–90.
502. The CAPS Investigators. The Cardiac Arrhythmia Pilot Study. Am J Cardiol 1986;57:91–5.
503. The CIBIS-II investigators. Lancet 1999;353:9–13.
504. The Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990;66:779–85.
505. The EPSIM Research Group. N Engl J Med. 1982;307:701–708.
506. The EUROPA investigators. Lancet 2003; 362: 7X2–788.
507. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329:383–9.
508. The GRACE Investigators. Am Heart J 2001;141:190–9.
509. The GUSTO Investigators. N Engl J Med 1993; 329:673–82.
510. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336:71–5.
511. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – A consensus document of the Joint European Society of Cardiology/American College of Cardiology for the redefinition of myocardial infarction. Eur Heart J 2000; 21:1502–13.
512. The LIPID Study Group. N Engl J Med 1998;339:1349–57. 214.
513. The MERIT-HF investigators. Lancet 1999;353:2001–7.
514. The Multicenter Postinfarction Research Group. N Eng J Med 1983;309:331–6.
515. The Sixth (2000) ACCP Guidelines for Antithrombotic Therapy for prevention and Treatment of Thrombois. Chest 2001;119:Suppl.
516. The TIMI Study Group. N Engl J Med 1989;320:618–27.
517. The Vth World Congress of Rehabilitation of Patients with Cardiovascular Diseases, Bordeaux, France, 5,07–8,07,1992.
518. Theroux P et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985; 5: 717–22.
519. Theroux P et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045–8.
520. Theroux P et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–11.
521. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and
522. non-Q-wave myocardial infarction. Circulation 1998; 97: 1195–206.
523. Thomas Almdal et al. Arch Intern Med 2004; 164:1422–6.
524. Thomas H. Marwick et al. J Am Coll Cardiol 2003;42:446–57.
525. Tien Yin Wong et al. BMJ 2004; 329:79.
526. Tiina Huittinen et al. Circulation 2003; 107: По материалам Cardiosite.ru...12,2014.
527. TIMI II A results. JAMA 1988;260:2849–58.
528. TIMI IIIA investigators. Circulation 1993;87: 38–52.
529. TIMI IIIB investigators. Circulation 1994; 89: 1545–56.
530. Tiziana Montalcini et al. Am J Cardiol 2004; 94:266–9.
531. Tobias Kurth et al. J Am Soc Nephrol 2003; 14:00–00.
532. Tobias Pischon et al. JAMA 2004; 291:1730–7.
533. Tommy Ohlenschkaeger et al. N Engl J Med 2004; 351:260–7.
534. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am. Heart. J. – 1993. – Vol. 125. – P. 667–672.
535. Topol EJ et al. The GUSTO V investigators. Lancet 2001;357:1905–14.
536. Torp-Pedersen C, Kober L. TRACE Study Group. Lancet 1999;354:9 – 12.
537. Trends in Ischemic Heart Disease Deaths – United States, 1990–1994.
538. MMWR February 21, 1997; 46; 7; 146–150.
539. Universal Definition of Myocardial Infarction. Circulation.2007; 116: 2634–2653 Published online before print October 19, 2007,doi: 10,1161/.
540. Uri Goldbourt et al. Arch Intern Med 2002; 162:993–9, 1013–9.
541. Van de Werf F et al. Task Force Report. Management of STEMI. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28–66.
542. van Domburg RT et al. Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol 1998; 31:1534–9.
543. van Es RF et al. The ASPECT-2 study. Lancet 2002; 360:109–13.
544. Vaughan Williams ME. Significance of classifying antiarrhythmic action since the cardiac arrhythmia suppression trial. J Clin Pharmacol 1991; 31(2):123–35.
545. Verdecchia P et al.: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the Piuma Study. Hypertension 2000, 36:1072.
546. Verghese J. et al. Neurology 2003; 61:1667–72.
547. Verheugt FWA. The APRICOT-2 trial. Presented 22th European Congress of Cardiology. Amsterdam, August. 2000.
548. Vermeer F et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999; 82:426–31.
549. Veronique Roger et al. JAMA 2004;292:344–50.
550. Verstraete M et al. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117: 1755–70.
551. Vitamin B6 And Homocysteine By Paul Frankel, Ph.D. and Terri Mitchell July 1997 http:.www.lef.org/magazine/mag97/july97_cover3.html
552. Wackers Frans, et al. Detection of Ischemia in Asymptomatic Diabetics. Diabetes Care 2004;27:1954–61.
553. Wallentin L et al. The ASSENT PLUS study. Clin Cardiol 2001;24(3 Suppl):I12–4.
554. Walter J. Koch et al. J Clin Invest 2003;112:999–1007.
555. Wei Jiang et al. Am Heart J 2003; 146:55–61.
556. Wei Jiang et al. Prevalence and Clinical Characteristics of Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart
557. Disease. J Am Coll Cardiol. 2013;61(7):714–722.
558. Weir CJ et al. Serum urate as an independent predictor of poor outcome and future vascular events after acune stroke. Stroke 2003;34:1951–1956.
559. Wells PS et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.. The New England journal of medicine. – 2003. – Vol. 349. – № 13. – P. 1227–1235.
560. White HD et al. HERO-2 Trial Investigators. Lancet 2001;358:1855–63.
561. White HD et al. HEROTrial Investigators. Circulation 1997;96:2155–61.
562. White HDet al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial. Circulation. – 1996. – Vol. 94. – P. 1826–1833.
563. WHO Expert Committee on Hypertension Control – Hypertension control. WHO techn report series № 862. Geneva 1996.
564. WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Circulation 1994;90:583–612.
565. Willem J. Kop et al. Psychosomat Med 2003; 65:396–401.
566. William J. Elliott et al. По материалам Reuters Health 2002 (http:.www.reutershealth.com/)
567. William Kannel et al. Am J Cardiol 2004;94:380–4.
568. William McKenna et al. Lancet 2003; 362:1429–31, 1457–9.
569. Willund I et al. Methods for assessing quality of life in the Cardiac Arrhythmia Suppression Trial (CAST). Qual Life Res 1992; 1(3):187–201.
570. Working Group on Rehabilitation of the European Society of Cardiology. Eur Heart J 1992;13 (Suppl C):1–45.
571. World Health Organization. WHO Technical Report Series 1999; 894.
572. Worldwide prevalence of anaemia 1993–2005. WHO Global Database on Anaemia. [Электронный ресурс] – Режим доступа: http:.whqlibdoc.who.int/publications/2008/9789241596657_eng.pdf [Дата обращения: 10.04.2014].
573. Wu AH et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999; 45: 1104–21.
574. Wu AH, Abbas SA, Green S et al. Prognostic value of cardiac troponin T in unstable angina pectoris. Am J Cardiol 1995; 76: 970–2.
575. Yan AT et al. Canadian ACS Registry Investigators. Am J Cardiol. 2005 Feb 1;95(3):438.
576. Ying Liu et al. Occup Environ Med 2002; 59:447–51.
577. Yusuf S et al. DAVIT-II and other recent studies. Am J Cardiol 1991; 67: 1295–7.
578. Yusuf S et al. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 2 of 2. Online J Curr Clin Trials 1994; Doc No. 144.
579. Yusuf S et al. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.
580. Zeeuw D. De Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association – European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.
581. Zehender M, Casper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis, after acute myocardial infarction. N Engl J Med 1993,325:981–8.
582. Zeymer U et al. ALKK-Study Group. Am Heart J 1999;137:34–8.
583. Zeymer U et al. HIT-4 Trial Group. J Am Coll Cardiol 1998;32:882–4.
584. Zipes DP. Basis electrophysiological principles, in Braunwald E. (ed): Heart Disease, ed 2. Philadelphia, WB Saunders Co, 1984;605–631.
585. Адамян К. Г. и соав. Коронарный резерв у больных инфарктом миокарда с зубцом Q и у больных инфарктом миокарда без зубца Q. Научные труды и сообщения НИЗ им академика С. Х. Авдалбекяна 1997; стр. 61–62.
586. Адамян К. Г., Аствацатрян А. А., Чилингарян А. Л. и соав. Спонтанное снижение общего холестерина в остром периоде инфарктом миокарда ассоциируется с большим количеством осложнений в раннем периоде заболевания. РНК. Кардиология, основанная на доказательствах Москва, 10–12 октября 2000; 21.
587. Адамян К. Г., Аствацатрян А. В. «Неклассические критерии» ЭКГ-позитивности нагрузочной пробы. Научные труды III конгресса кардиологов Армении, Ереван 2001; 7–11.
588. Адамян К. Г., Аствацатрян А. В. Гипергликемия в острой стадии инфаркта миокарда − предиктор смертности. Научные труды VI конгресса кардиологов Армении. Ереван. Май 2007. 4–8.
589. Адамян К. Г., Аствацатрян А. В. Острый коронарный синдром. Ведение больного на этапе блока интенсивной терапии. Медицинская наука Армении 2004, т. XLIV, № 2; 3–8.
590. Адамян К. Г., Аствацатрян А. В. Острый коронарный синдром. Этиопатофизиология и диагностика. Медицинская наука Армении 2003, т. XLIII, № 4; 3–8.
591. Адамян К. Г., Аствацатрян А. В., Чилингарян А. Л. Острый коронарный синдром. Руководство. Киев. 2006. ООО «Четверта хвиля». 311 стр.
592. Адамян К. Г., Чилингарян А. Л., Аствацатрян А. В. и соав. Феномен элевации сегмента ST при нагрузочной пробе после тромболизиса в остром периоде инфаркта миокарда и последующее развитие ремоделирование левого желудочка. РНК. «Кардиология: Эффективность и безопасность диагностики и лечения» 2001; 25.
593. Амосов Н. М. http:.www.icfcst.kiev.ua/AMOSOV/books_r.html. 1,2015
594. Аронов Д. М. Диагностика и лечение хронической ишемической болезни сердца. 2005. http:.www.kardiology.ru./doctors/ibs.html.
595. Арутюнов Г. П. Статины и острый коронарный синдром. Мы на пороге нового стандарта лечения. Сердце 2002; 1(1): 44–46.
596. Аствацатрян А. В. «600 страниц об остром коронарном синдроме» http:.www.publicant.ru/book.aspx?id_d=386665 (12,2014).
597. Аствацатрян А. В. Ишемическая болезнь сердца: некоторые проблемы на современном этапе. Лекарства и медицина 2000, 2; 55–61.
598. Аствацатрян А. В. Острый коронарный синдром. Оценка риска и стратегия ведения. Медицинская наука Армении 2003, т. XLIII, № 4; 57–61.
599. Аствацатрян А. В. Острый коронарный синдром. Принципы медикаментозной терапии. Медицинская наука Армении 2003, т. XLIV, № 3; 3–10.
600. Аствацатрян А. В. Что такое холестерол и как с ним бороться? Лекарства и медицина N 1;59–62.
601. Аствацатрян А. В.Ишемическая болезнь сердца: некоторые проблемы на современном этапе. Лекарства и медицина 2000, 2; 55–61.
602. Барскова В. Г., Насонова В. А. Подагра и синдром инсулинорезистентности. Рус мед журн 2003;11:23:1299–1301.
603. Билецкий С. В. Эндотеалиальная дисфункция и патология сердечно-сосудистой системы. Внутренняя медицина – 2008. 2(8).
604. Ганс Селье. Очерки об адаптационном синдроме. Медгиз 1960. Москва.
605. Гриффин Б., Тополь Э. «Кардиология» Москва, 2008. Демографические ежегодники Российской Федерации. С 1993 по 1995. Госкомстат России. ~ М., 1994–1996.
606. Затейщикова А. А., Затейщиков Д. А. Эндотелиальная регуляция сосудистого тонуса: методы исследования и клиническое значение. Кардиология. – 1998. – Т. 38, № 9. – С. 68–80.
607. Кириченко А. А. Депрессия, беспокойство и сердечно-сосудистая система. Лечащий врач. 2002/ 02.
608. Кобалава Ж. Д., Толкачева В. В., Караулова Ю. Л. Мочевая кислота – маркер и/или новый фактор риска развития сердечно-сосудистых осложнений? РМЖ 2002; 10:10:431–436.
609. Коваленко В. Н. «Руководство по кардиологии» Киев, 2008.
610. Корзун А. И., Кириллова М. В. Сравнительная характеристика ингибиторов ГМГ-КоА-редуктазы (статинов). clinicallectures/article.asp?id=1749. Обращение к сайту – 19,02,2005.
611. Крюков Н. Н., Николаевский Е. Н. «Ишемическая болезнь сердца» Самара, 2010.
612. Лутай М. И. Атеросклероз: современный взгляд на патогенез. Укр. кардіол. журн. – 2004. – № 1. – С. 22–34.
613. Мазур Н. А. Профилактика внезапной смерти у больных после инфаркта миокарда. Доклад 11 октября 2006 года в рамках Российского национального конгресса кардиологов.
614. Мычка В. Б. Метаболический синдром как понятие в клинике внутренних болезней. Доклад на сателлитный симпозиуме фармацевтической компании Солвей Фарма «Факторы риска и пути их коррекции у пациентов с метаболическим синдромом», прошедший в рамках Конгресса терапевтов 2 ноября 2006 года.
615. Образцов В. П., Стражеско Н. Д. «Zeitschrift fur Klinische medizinae» 71:116,1910
616. Ольбинская Л. И., Литвицкий П. Ф. Коронарная и миокардиальная недостаточность. Москва «Медицина», 1986. 254 с.
617. Российский статистический ежегодник: Статистический сборник. Офиц. изд. Госкомстат России. ~ М., 1994–1996.
618. Руда М. Я. и соав. «Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST». «Кардиоваскулярная терапия и профилактика» 2007; 6 (8), Приложение 1.
619. Сергиенко В. Б., Саютина Е. В., Самойленко Л. Е. и др. Роль дисфункции эндотелия в развитии ишемии миокарда у больных ишемической болезнью сердца с неизмененными и малоизмененными коронарными артериями. Кардиология. – 1999. – Т. 39, № 1. – С. 25–30.
620. Сторожаков Г. И., Верещагина Г. С., Малышева Н. В. Эндотелиальная дисфункция при артериальной гипертонии у пациентов пожилого возраста. Клиническая геронтология. – 2003. – Т. 9, № 1. – С. 23–28.
621. Сыркин А. Л., Добровольский А. В. Острый коронарный синдром без подъема сегмента ST на ЭКГ. На сайте www.medlinks.ru
622. Темникова Е. С. Сердечно-сосудистые заболевания и анемия. Лечащий врач. #06,14.
623. Целуйко В. И., Мищук Н. Е. Статины в лечении больных с инфарктом миокарда. Практическая ангиология. 6/2 август 2009.
624. Чазов Е. И. Пути повышения эффективности лечения ишемической болезни сердца. Тер. архив 1997;9:5–10.
625. Чазов Е. И. Руководство по кардиологии. Т. 3. Болезни сердца. Москва «Медицина» 1982;624 с.
626. Черкашин Д. В. Клиническое значение и коррекция эндотелиальной дисфункции. Кафедра военно-морской и общей терапии Военно-Медицинской Академии. 2004; По материалам Cardiosite.ru.
627. Шкала риска Framingham (http:.www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf, http:.www.chd-taskforce.de/pdf/pocket_guide_engl.pdf)
628. Шкала риска PROCAM (http:.www.chd-taskforce.com, http:.www.chd-taskforce.de/pdf/pocket_guide_engl.pdf)

MARC record